达格列净与慢性肾脏病或心力衰竭患者新发2型糖尿病:DAPA-CKD和DAPA-HF试验的汇总分析
本汇总分析纳入DAPA-CKD和DAPA-HF两项试验中无糖尿病史且基线HbA1c低于6.5%的4003例患者,评估达格列净对新发2型糖尿病的影响。中位随访21.2个月,达格列净组新发2型糖尿病风险低于安慰剂组(HR 0.67,95%CI 0.51-0.88;p=0.0040),且HbA1c无降低。
要点
- 在慢性肾脏病和心力衰竭患者中,达格列净降低新发2型糖尿病风险(HR 0.67)。
- 达格列净组新发糖尿病事件率2.6/100患者年,安慰剂组3.9/100患者年。
- 发生2型糖尿病的参与者中超过90%基线时为糖尿病前期。
核心结论
- 达格列净治疗降低了慢性肾脏病和心力衰竭参与者新发2型糖尿病的发生率,且未伴随HbA1c降低。
研究设计与样本
- 本研究是对两项3期、随机、双盲、安慰剂对照、多中心临床试验(DAPA-CKD和DAPA-HF)个体参与者数据的汇总分析。
- 纳入基线无糖尿病史且HbA1c低于6.5%(48 mmol/mol)的参与者,共4003例(DAPA-CKD试验1398例[34.9%],DAPA-HF试验2605例[65.1%])。
- 1995例(49.8%)接受达格列净,2008例(50.2%)接受安慰剂。
- 新发2型糖尿病定义为连续两次HbA1c≥6.5%(≥48 mmol/mol)或试验访视间临床诊断糖尿病,采用Cox比例风险模型分析从随机分组至治疗结束的时间。
主要发现
- 中位随访21.2个月(IQR 16.0至25.4),安慰剂组2008例中126例(6.3%)发生2型糖尿病(事件率3.9/100患者年),达格列净组1995例中85例(4.3%)发生2型糖尿病(事件率2.6/100患者年),风险比0.67(95%CI 0.51至0.88;p=0.0040)。
- 研究间无异质性(交互作用p=0.77),预设亚组(包括性别、年龄、血糖状态、BMI、肾小球滤过率、收缩压和基线心血管药物使用)中达格列净效应无明确差异。
- 发生2型糖尿病的参与者中超过90%基线时为糖尿病前期(HbA1c 5.7%至6.4%[39至46 mmol/mol])。
- 12个月时,达格列净组经安慰剂校正的HbA1c平均变化为-0.01%(95%CI -0.03至0.01),-0.1 mmol/mol(95%CI -0.3至0.1),平均HbA1c保持不变。
关键数值与推荐
- 新发2型糖尿病风险:达格列净组 vs 安慰剂组 HR 0.67(95%CI 0.51至0.88;p=0.0040)。
- 事件率:达格列净组2.6/100患者年 vs 安慰剂组3.9/100患者年。
- 12个月HbA1c经安慰剂校正的变化:-0.01%(95%CI -0.03至0.01),-0.1 mmol/mol(95%CI -0.3至0.1)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic kidney disease and heart failure are insulin resistant states associated with a high incidence of diabetes. We assessed the effect of dapagliflozin on new-onset type 2 diabetes in a pooled analysis of patient-level data from the DAPA-CKD and DAPA-HF trials. METHODS: This study is a pooled analysis of individual participant data from two phase 3, randomised, double-blind, placebo-controlled, multicentre, clinical trials. Participants with no history of diabetes and HbA1c less than 6·5% (48 mmol/mol) at baseline were included in this pooled analysis. New-onset type 2 diabetes was a prespecified exploratory endpoint in both DAPA-CKD and DAPA-HF trials and is the focus of this analysis. New-onset type 2 diabetes was identified by serial trial measurements of HbA1c (two consecutive values ≥6·5% [≥48 mmol/mol]) or following a clinical diagnosis of diabetes between trial visits. Time to new-onset type 2 diabetes was analysed in a Cox proportional Hazards model from random assignment to end of treatment. FINDINGS: 4003 participants (1398 [34·9%] from the DADA-CKD trial and 2605 [65·1%] from the DAPA-HF trial) were included in our analysis: 1995 (49·8%) had received dapagliflozin and 2008 (50·2%) had received placebo. Over a median follow-up of 21·2 months (IQR 16·0 to 25·4), 126 (6·3%) of 2008 patients in the placebo group (event rate 3·9 per 100 patient-years) and 85 (4·3%) of 1995 patients in the dapagliflozin group (event rate 2·6 per 100 patient-years) developed type 2 diabetes (hazard ratio 0·67 [95% CI 0·51 to 0·88]; p=0·0040). There was no heterogeneity between studies (p interaction 0·77) and there was no clear evidence that the effect of dapagliflozin varied in prespecified subgroups including sex, age, glycaemic status, BMI, glomerular filtration rate, systolic blood pressure, and baseline cardiovascular medication use. More than 90% of the participants who developed type 2 diabetes had prediabetes at baseline (HbA1c 5·7% to 6·4% [39 to 46 mmol/mol]). Mean HbA1c remained unchanged (placebo-adjusted change in the dapagliflozin group of -0·01% [95% CI -0·03 to 0·01], -0·1 mmol/mol [95% CI -0·3 to 0·1] at 12 months). INTERPRETATION: Treatment with dapagliflozin reduced the incidence of new-onset type 2 diabetes in participants with chronic kidney disease and HF without a reduction in HbA1c. FUNDING: AstraZeneca.
引用
- Rossing P, Inzucchi SE, Vart P, et al. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol. 2021. PMID: 34856173. doi:10.1016/S2213-8587(21)00295-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。